MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis

Atherosclerosis

Volumn 242, Issue 2, 2015, Pages 595-604

  Alvarez, M Lucrecia ^a   Khosroheidari, Mahdieh ^a   Eddy, Elena ^a   Done, Stefania C ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Cholesterol homeostasis; LDLR; LDLRAP1; LRP6; MiR 27a; PCSK9

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR ADAPTER PROTEIN 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MESSENGER RNA; MICRORNA; MICRORNA 23A; MICRORNA 24; MICRORNA 24 2; MICRORNA 27A; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CHOLESTEROL; LDLR PROTEIN, HUMAN; LDLRAP1 PROTEIN, HUMAN; LIPOPROTEIN; MIRN23 MICRORNA, HUMAN; MIRN24 MICRORNA, HUMAN; MIRN27 MICRORNA, HUMAN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; ATHEROSCLEROSIS; BASE PAIRING; BINDING SITE; CHOLESTEROL HOMEOSTASIS; CHOLESTEROL METABOLISM; CHROMOSOME 19; CONTROLLED STUDY; DOWN REGULATION; ENDOCYTOSIS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LIPID HOMEOSTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; UPREGULATION; WESTERN BLOTTING; BIOLOGY; BLOOD; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; HOMEOSTASIS; LIVER; METABOLISM; POLYMERASE CHAIN REACTION; RISK FACTOR;

3' UNTRANSLATED REGIONS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ATHEROSCLEROSIS; CHOLESTEROL; COMPUTATIONAL BIOLOGY; ENDOCYTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEP G2 CELLS; HOMEOSTASIS; HUMANS; LIPOPROTEINS; LIVER; MICRORNAS; POLYMERASE CHAIN REACTION; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RISK FACTORS; SERINE ENDOPEPTIDASES; TRANSFECTION;

EID: 84940094557     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.023     Document Type: Article

References (49)

1. Contu R., Latronico M.V., Condorelli G. Circulating microRNAs as potential biomarkers of coronary artery disease: a promise to be fulfilled?. Circ. Res. 2010, 107:573-574.
2. Go G.W., Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J. Biol. Med. 2012, 85:19-28.
3. Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015, 131:e29-322.
4. Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 2009, 29:431-438.
5. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34:154-156.
6. Michaely P., Li W.P., Anderson R.G., et al. The modular adaptor protein ARH is required for low density lipoprotein (LDL) binding and internalization but not for LDL receptor clustering in coated pits. J. Biol. Chem. 2004, 32:34023-34031.
7. Ye Z.J., Go G.W., Singh R., et al. LRP6 protein regulates low density lipoprotein (LDL) receptor-mediated LDL uptake. J. Biol. Chem. 2012, 287:1335-1344.
8. Kidd J. Life after statin patent expiries. Nat. Rev. Drug Discov. 2006, 10:813-814.
9. Dong B., Wu M., Li H., et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res. 2010, 51:1486-1495.
10. Athyros V.G., Katsiki N., Karagiannis A., et al. High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. J. Diabetes Complicat. 2015, 29:142-145.
11. Hegland O., Kurz M.W., Munk P.S., et al. The effect of statin therapy on the progression of carotid artery stenosis in relation to stenosis severity. Acta Neurol. Scand. 2010, 121:11-15.
12. Karalis D.G., Victor B., Ahedor L., et al. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol 2012, 1-7. 861924.
13. Reiner Z. Resistance and intolerance to statins. Nutr. Metab. Cardiovasc. Dis. 2014, 24:1057-1066.
14. Fernandez-Hernando C., Moore K.J. MicroRNA modulation of cholesterol homeostasis. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2378-2382.
15. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
16. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
17. Beekman M., Heijmans B.T., Martin N.G., et al. Evidence for a QTL on chromosome 19 influencing LDL cholesterol levels in the general population. Eur. J. Hum. Genet. 2003, 11:845-850.
18. Imperatore G., Knowler W.C., Pettitt D.J., et al. A locus influencing total serum cholesterol on chromosome 19p: results from an autosomal genomic scan of serum lipid concentrations in Pima Indians. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2651-2656.
19. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
20. Grimson A., Farh K.K., Johnston W.K., et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
21. John B., Enright A.J., Aravin A., et al. Human microRNA targets. PLoS Biol. 2004, 2:e363.
22. Alvarez M.L., Done S.C. SYBR(R) Green and TaqMan(R) quantitative PCR arrays: expression profile of genes relevant to a pathway or a disease state. Methods Mol. Biol. 2014, 1182:321-359.
23. Alvarez M.L. Faster experimental validation of microRNA targets using cold fusion cloning and a dual firefly-renilla luciferase reporter assay. Methods Mol. Biol. 2014, 1182:227-243.
24. Landgraf P., Rusu M., Sheridan R., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129:1401-1414.
25. Barad O., Meiri E., Avniel A., et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res. 2004, 14:2486-2494.
26. Chen X.M. MicroRNA signatures in liver diseases. World J. Gastroenterol. 2009, 15:1665-1672.
27. Fu H., Tie Y., Xu C., et al. Identification of human fetal liver miRNAs by a novel method. FEBS Lett. 2005, 579:3849-3854.
28. Zhang M., Wu J.F., Chen W.J., et al. MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages. Atherosclerosis 2014, 234:54-64.
29. Place R.F., Li L.C., Pookot D., et al. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1608-1613.
30. Ellwanger D.C., Buttner F.A., Mewes H.W., et al. The sufficient minimal set of miRNA seed types. Bioinformatics 2011, 10:1346-1350.
31. Esau C., Davis S., Murray S.F., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3:87-98.
32. Iliopoulos D., Drosatos K., Hiyama Y., et al. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J. Lipid Res. 2010, 51:1513-1523.
33. Rayner K.J., Suarez Y., Davalos A., et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010, 328:1570-1573.
34. Najafi-Shoushtari S.H., Kristo F., Li Y., et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010, 328:1566-1569.
35. Chen W.J., Yin K., Zhao G.J., et al. The magic and mystery of microRNA-27 in atherosclerosis. Atherosclerosis 2012, 222:314-323.
36. Vickers K.C., Shoucri B.M., Levin M.G., et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 2013, 57:533-542.
37. Choi J.E., Hur W., Kim J.H., et al. MicroRNA-27a modulates HCV infection in differentiated hepatocyte-like cells from adipose tissue-derived mesenchymal stem cells. PLoS One 2014, 9:e91958.
38. Li S., Li J.J. PCSK9: a key factor modulating atherosclerosis. J. Atheroscler. Thromb. 2015, 22:221-230.
39. Huang V., Place R.F., Portnoy V., et al. Upregulation of cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 2012, 40:1695-1707.
40. He G., Gupta S., Yi M., et al. ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2. J. Biol. Chem. 2002, 277:44044-44049.
41. Karolina D.S., Tavintharan S., Armugam A., et al. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 2012, 97:E2271-E2276.
42. Nielsen L.B., Wang C., Sorensen K., et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp. Diabetes Res. 2012, 2012. 896362.
43. Herrera B.M., Lockstone H.E., Taylor J.M., et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010, 53:1099-1109.
44. Xie H., Sun L., Lodish H.F. Targeting microRNAs in obesity. Expert Opin. Ther. Targets 2009, 10:1227-1238.
45. Alisi A., Da Sacco L., Bruscalupi G., et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab. Invest. 2011, 2:283-293.
46. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010, 103:71-83.
47. Monaco C., Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc. Res. 2004, 4:671-682.
48. Dubuc G., Chamberland A., Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1454-1459.
49. Lindholm M.W., Elmen J., Fisker N., et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol. Ther. 2012, 20:376-381.